Detalles de la búsqueda
1.
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
N Engl J Med
; 380(25): 2406-2417, 2019 06 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31075187
2.
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
Mult Scler
; 28(1): 111-120, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33969750
3.
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Mult Scler
; 25(6): 819-827, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29716436
4.
Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis.
Br J Clin Pharmacol
; 85(7): 1484-1494, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30883839
5.
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Mult Scler
; 24(12): 1594-1604, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28870107
6.
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
Mult Scler
; 24(2): 222-226, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28140753
7.
Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
BMC Neurol
; 18(1): 143, 2018 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-30217172
8.
Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.
BMC Neurol
; 18(1): 68, 2018 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29751787
9.
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
BMC Neurol
; 15: 232, 2015 Nov 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-26559139
10.
In vitro assessment of the biologic activity of interferon beta formulations used for the treatment of relapsing multiple sclerosis.
J Immunoassay Immunochem
; 35(3): 288-99, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24654824
11.
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.
Neurol Ther
; 13(2): 283-322, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38206453
12.
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
BMC Neurol
; 13: 80, 2013 Jul 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-23841877
13.
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonß-1a versus subcutaneous interferonß-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
BMC Neurol
; 12: 154, 2012 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23216674
14.
Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.
Clin Transl Sci
; 15(12): 2888-2898, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36126241
15.
Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
Neurodegener Dis Manag
; 12(6): 295-301, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36017780
16.
The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
Neurodegener Dis Manag
; 12(6): 285-293, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35920065
17.
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.
Neurodegener Dis Manag
; 12(1): 1-7, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35019731
18.
Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
Neurodegener Dis Manag
; 12(6): 303-310, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36017797
19.
Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment.
Curr Med Res Opin
; 37(3): 459-464, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33331183
20.
Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION.
J Neuroimmunol
; 360: 577715, 2021 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34536787